51
|
Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy - an update from drug design perspective. Drug Des Devel Ther 2017; 11:599-616. [PMID: 28424538 PMCID: PMC5344412 DOI: 10.2147/dddt.s119488] [Citation(s) in RCA: 600] [Impact Index Per Article: 75.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
In the past, metal-based compounds were widely used in the treatment of disease conditions, but the lack of clear distinction between the therapeutic and toxic doses was a major challenge. With the discovery of cisplatin by Barnett Rosenberg in 1960, a milestone in the history of metal-based compounds used in the treatment of cancers was witnessed. This forms the foundation for the modern era of the metal-based anticancer drugs. Platinum drugs, such as cisplatin, carboplatin and oxaliplatin, are the mainstay of the metal-based compounds in the treatment of cancer, but the delay in the therapeutic accomplishment of other metal-based compounds hampered the progress of research in this field. Recently, however, there has been an upsurge of activities relying on the structural information, aimed at improving and developing other forms of metal-based compounds and nonclassical platinum complexes whose mechanism of action is distinct from known drugs such as cisplatin. In line with this, many more metal-based compounds have been synthesized by redesigning the existing chemical structure through ligand substitution or building the entire new compound with enhanced safety and cytotoxic profile. However, because of increased emphasis on the clinical relevance of metal-based complexes, a few of these drugs are currently on clinical trial and many more are awaiting ethical approval to join the trial. In this review, we seek to give an overview of previous reviews on the cytotoxic effect of metal-based complexes while focusing more on newly designed metal-based complexes and their cytotoxic effect on the cancer cell lines, as well as on new approach to metal-based drug design and molecular target in cancer therapy. We are optimistic that the concept of selective targeting remains the hope of the future in developing therapeutics that would selectively target cancer cells and leave healthy cells unharmed.
Collapse
Affiliation(s)
- Umar Ndagi
- Molecular Modelling and Drug Design Research Group, School of Health Sciences, University of KwaZulu-Natal, Westville, Durban, South Africa
| | - Ndumiso Mhlongo
- Molecular Modelling and Drug Design Research Group, School of Health Sciences, University of KwaZulu-Natal, Westville, Durban, South Africa
| | - Mahmoud E Soliman
- Molecular Modelling and Drug Design Research Group, School of Health Sciences, University of KwaZulu-Natal, Westville, Durban, South Africa
| |
Collapse
|
52
|
Guler E, Demir B, Guler B, Demirkol DO, Timur S. BiofuNctionalized nanomaterials for targeting cancer cells. NANOSTRUCTURES FOR CANCER THERAPY 2017:51-86. [DOI: 10.1016/b978-0-323-46144-3.00003-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2025]
|
53
|
Bhadra U, Patra P, Chhatai J, Pal-Bhadra M. Pigmy MicroRNA: surveillance cops in Therapies kingdom. Mol Med 2016; 22:759-775. [PMID: 27704139 PMCID: PMC5193465 DOI: 10.2119/molmed.2016.00136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 09/13/2016] [Indexed: 11/06/2022] Open
Abstract
MicroRNAs (miRNAs) are well preserved in every animal. These pigmy sized non-coding RNAs (21-23 nt), scattered in genome, are responsible for micromanaging the versatile gene regulations. Involvement of miRNAs was surveillance cops in all human diseases including cardiovascular defects, tumor formation, reproductive pathways, and neurological and autoimmune disorders. The effective functional role of miRNA can be reduced by chemical entities of antisense oligonucleotides and versatile small molecules that support the views of novel therapy of different human diseases. In this study, we have updated our current understanding for designing and synthesizing miRNA-controlling therapeutic chemicals. We have also proposed various in-vivo delivery strategies and their ongoing challenges to combat the incorporation hurdles in live cells and animals. Lastly, we have demonstrated the current progress of miRNA modulation in the treatment of different human diseases that provides an alternative approach of gene therapy.
Collapse
Affiliation(s)
- Utpal Bhadra
- Functional Genomics and Gene Silencing Group, Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, India
| | - Pradipta Patra
- Functional Genomics and Gene Silencing Group, Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, India
| | - Jagamohan Chhatai
- Functional Genomics and Gene Silencing Group, Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, India
| | - Manika Pal-Bhadra
- Centre for Chemical Biology, Indian Institute of Chemical Technology, Uppal Road, Hyderabad, India
| |
Collapse
|
54
|
Aberoumandi SM, Mohammadhosseini M, Abasi E, Saghati S, Nikzamir N, Akbarzadeh A, Panahi Y, Davaran S. An update on applications of nanostructured drug delivery systems in cancer therapy: a review. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2016; 45:1-11. [PMID: 27632797 DOI: 10.1080/21691401.2016.1228658] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Cancer is a main public health problem that is known as a malignant tumor and out-of-control cell growth, with the potential to assault or spread to other parts of the body. Recently, remarkable efforts have been devoted to develop nanotechnology to improve the delivery of anticancer drug to tumor tissue as minimizing its distribution and toxicity in healthy tissue. Nanotechnology has been extensively used in the advance of new strategies for drug delivery and cancer therapy. Compared to customary drug delivery systems, nano-based drug delivery method has greater potential in different areas, like multiple targeting functionalization, in vivo imaging, extended circulation time, systemic control release, and combined drug delivery. Nanofibers are used for different medical applications such as drug delivery systems.
Collapse
Affiliation(s)
- Seyed Mohsen Aberoumandi
- a Department of Clinical Sciences, Tabriz Branch , Islamic Azad University , Tabriz , Iran.,b Young Researchers and Elite Club, Tabriz Branch , Islamic Azad University , Tabriz , Iran.,e Chemical Injuries Research Center , Baqiyatallah University of Medical Sciences , Tehran , Iran
| | | | - Elham Abasi
- c Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran
| | - Sepideh Saghati
- c Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.,i Student Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran
| | - Nasrin Nikzamir
- g Universal Scientific Education and Research Network (USERN) , Tabriz , Iran.,h Department of Basic Sciences , Science and Research Branch, Islamic Azad University , Tehran , Iran
| | - Abolfazl Akbarzadeh
- c Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.,d Biotechnology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.,g Universal Scientific Education and Research Network (USERN) , Tabriz , Iran.,i Student Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran
| | - Yunes Panahi
- e Chemical Injuries Research Center , Baqiyatallah University of Medical Sciences , Tehran , Iran
| | - Soodabeh Davaran
- c Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.,d Biotechnology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran
| |
Collapse
|
55
|
Abstract
microRNAs (miRNA) are small non-coding RNAs (sRNA) that post-transcriptionally regulate gene (mRNA) expression and are implicated in many biological processes and diseases. Many miRNAs have been reported to be altered in cardiovascular disease (CVD); both cellular and extracellular miRNA levels are affected by hypercholesterolemia and atherosclerosis. We and other groups have reported that lipoproteins transport miRNAs in circulation and these lipoprotein signatures are significantly altered in hypercholesterolemia and coronary artery disease (CAD). Extracellular miRNAs are a new class of potential biomarkers for CVD; however, they may also be new drug targets as high-density lipoproteins (HDL) transfer functional miRNAs to recipient cells in an endocrine-like form of intercellular communication that likely suppresses vascular inflammation. Recently, RNA-based drugs have emerged as the next frontier in drug therapy, and there are many miRNA inhibitors and mimics in clinical development. Here, we discuss specific miRNA drug targets and how their manipulation may impact CVD. We also address the potential for manipulating HDL-miRNA levels to treat CVD and the use of HDL as a delivery vehicle for RNA and chemical drugs. Finally, we outline the current and future challenges for HDL and miRNA-based therapeutics for the prevention and treatment of CVD.
Collapse
Affiliation(s)
- Danielle L Michell
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Kasey C Vickers
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
| |
Collapse
|
56
|
Nanocarriers based delivery of nutraceuticals for cancer prevention and treatment: A review of recent research developments. Trends Food Sci Technol 2016. [DOI: 10.1016/j.tifs.2016.06.003] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
57
|
Shahbazi R, Ozpolat B, Ulubayram K. Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond) 2016; 11:1287-308. [PMID: 27102380 DOI: 10.2217/nnm-2016-0035] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Theranostic approaches, combining the functionality of both therapy and imaging, have shown potential in cancer nanomedicine. Oligonucleotides such as small interfering RNA and microRNA, which are powerful therapeutic agents, have been effectively employed in theranostic systems against various cancers. Nanoparticles are used to deliver oligonucleotides into tumors by passive or active targeting while protecting the oligonucleotides from nucleases in the extracellular environment. The use of quantum dots, iron oxide nanoparticles and gold nanoparticles and tagging with contrast agents, like fluorescent dyes, optical or magnetic agents and various radioisotopes, has facilitated early detection of tumors and evaluation of therapeutic efficacy. In this article, we review the advantages of theranostic applications in cancer therapy and imaging, with special attention to oligonucleotide-based therapeutics.
Collapse
Affiliation(s)
- Reza Shahbazi
- Department of Nanotechnology & Nanomedicine, Institute for Graduate Studies in Science & Engineering, Hacettepe University, Ankara 06532, Turkey
| | - Bulent Ozpolat
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Kezban Ulubayram
- Department of Nanotechnology & Nanomedicine, Institute for Graduate Studies in Science & Engineering, Hacettepe University, Ankara 06532, Turkey.,Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Turkey.,Department of Bioengineering, Institute for Graduate Studies in Science & Engineering, Hacettepe University, Ankara 06532, Turkey
| |
Collapse
|
58
|
Mendes R, Carreira B, Baptista PV, Fernandes AR. Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2016. [DOI: 10.1080/23808993.2016.1159914] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
59
|
Uckun FM, Qazi S, Cheng J. Targeting leukemic stem cells with multifunctional bioactive polypeptide nanoparticles. Future Oncol 2016; 11:1149-52. [PMID: 25832872 DOI: 10.2217/fon.15.31] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Fatih M Uckun
- Children's Center for Cancer & Blood Diseases, Children's Hospital Los Angeles (CHLA), Los Angeles, CA 90027, USA
| | | | | |
Collapse
|
60
|
ANDRÉ NAYARADELGADO, SILVA VIVIANEALINEOLIVEIRA, WATANABE MARIAANGELICAEHARA, DE LUCCA FERNANDOLUIZ. Knockdown of chemokine receptor CXCR4 gene by RNA interference: Effects on the B16-F10 melanoma growth. Oncol Rep 2016; 35:2419-24. [DOI: 10.3892/or.2016.4620] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 11/04/2015] [Indexed: 11/06/2022] Open
|
61
|
Pawar A, Rajalakshmi S, Mehta P, Shaikh K, Bothiraja C. Strategies for formulation development of andrographolide. RSC Adv 2016. [DOI: 10.1039/c6ra12161f] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
This review is the comprehensive account of the pharmaceutical aspects of andrographolide with special emphasis on its delivery that have take place over the century.
Collapse
Affiliation(s)
- Atmaram Pawar
- Department of Pharmaceutics
- Bharati Vidyapeeth Deemed University
- Poona College of Pharmacy
- Pune 411038
- India
| | - S. Rajalakshmi
- Department of Pharmaceutics
- Padmashree Dr D. Y. Patil College of Pharmacy
- Pune-411044
- India
| | - Piyush Mehta
- Department of Pharmaceutics
- Bharati Vidyapeeth Deemed University
- Poona College of Pharmacy
- Pune 411038
- India
| | | | - Chellampillai Bothiraja
- Department of Pharmaceutics
- Bharati Vidyapeeth Deemed University
- Poona College of Pharmacy
- Pune 411038
- India
| |
Collapse
|
62
|
Kadri R, Ben Messaoud G, Tamayol A, Aliakbarian B, Zhang HY, Hasan M, Sánchez-González L, Arab-Tehrany E. Preparation and characterization of nanofunctionalized alginate/methacrylated gelatin hybrid hydrogels. RSC Adv 2016. [DOI: 10.1039/c6ra03699f] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
We developed the preparation of alginate/methacrylated gelatin (GelMA) hybrid hydrogels functionalized with nanoliposomes encapsulating curcumin.
Collapse
Affiliation(s)
- R. Kadri
- Laboratoire d'ingénierie des biomolécules (LIBio)
- ENSAIA-Université de Lorraine
- 54518 Vandoeuvre-lès-Nancy Cedex
- France
| | - G. Ben Messaoud
- Laboratoire d'ingénierie des biomolécules (LIBio)
- ENSAIA-Université de Lorraine
- 54518 Vandoeuvre-lès-Nancy Cedex
- France
| | - A. Tamayol
- Biomaterials Innovation Research Center
- Division of Biomedical Engineering
- Department of Medicine
- Brigham and Women's Hospital
- Harvard Medical School
| | - B. Aliakbarian
- Department of Civil
- Chemical and Environmental Engineering (DICCA)
- University of Genoa
- Genoa
- Italy
| | - H. Y. Zhang
- Université de Lorraine
- Institut Jean Lamour UMR 7198 CNRS
- 54042 Nancy
- France
| | - M. Hasan
- Laboratoire d'ingénierie des biomolécules (LIBio)
- ENSAIA-Université de Lorraine
- 54518 Vandoeuvre-lès-Nancy Cedex
- France
| | - L. Sánchez-González
- Laboratoire d'ingénierie des biomolécules (LIBio)
- ENSAIA-Université de Lorraine
- 54518 Vandoeuvre-lès-Nancy Cedex
- France
| | - E. Arab-Tehrany
- Laboratoire d'ingénierie des biomolécules (LIBio)
- ENSAIA-Université de Lorraine
- 54518 Vandoeuvre-lès-Nancy Cedex
- France
| |
Collapse
|
63
|
Woldemichael BT, Mansuy IM. Micro-RNAs in cognition and cognitive disorders: Potential for novel biomarkers and therapeutics. Biochem Pharmacol 2015; 104:1-7. [PMID: 26626188 DOI: 10.1016/j.bcp.2015.11.021] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Accepted: 11/20/2015] [Indexed: 12/31/2022]
Abstract
Micro-RNAs (miRNAs) are small regulatory non-coding RNAs involved in the regulation of many biological functions. In the brain, they have distinct expression patterns depending on region, cell-type and developmental stage. Their expression profile is altered by neuronal activation in response to behavioral training or chemical/electrical stimulation. The dynamic changes in miRNA level regulate the expression of genes required for cognitive processes such as learning and memory. In addition, in cognitive dysfunctions such as dementias, expression levels of many miRNAs are perturbed, not only in brain areas affected by the pathology, but also in peripheral body fluids such as serum and cerebrospinal fluid. This presents an opportunity to utilize miRNAs as biomarkers for early detection and assessment of cognitive dysfunctions. Further, since miRNAs target many genes and pathways, they may represent key molecular signatures that can help understand the mechanisms of cognitive disorders and the development of potential therapeutic agents.
Collapse
Affiliation(s)
- Bisrat T Woldemichael
- Brain Research Institute, Lab of Neuroepigenetics, Neuroscience Center Zürich, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland
| | - Isabelle M Mansuy
- Brain Research Institute, Lab of Neuroepigenetics, Neuroscience Center Zürich, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland.
| |
Collapse
|
64
|
Legaz S, Exposito JY, Borel A, Candusso MP, Megy S, Montserret R, Lahaye V, Terzian C, Verrier B. A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in cellulo. Protein Expr Purif 2015; 113:94-101. [PMID: 26002116 DOI: 10.1016/j.pep.2015.05.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Revised: 05/06/2015] [Accepted: 05/12/2015] [Indexed: 11/24/2022]
Abstract
Gal4/UAS system is a powerful tool for the analysis of numerous biological processes. Gal4 is a large yeast transcription factor that activates genes including UAS sequences in their promoter. Here, we have synthesized a minimal form of Gal4 DNA sequence coding for the binding and dimerization regions, but also part of the transcriptional activation domain. This truncated Gal4 protein was expressed as inclusion bodies in Escherichia coli. A structured and active form of this recombinant protein was purified and used to cover poly(lactic acid) (PLA) nanoparticles. In cellulo, these Gal4-vehicles were able to activate the expression of a Green Fluorescent Protein (GFP) gene under the control of UAS sequences, demonstrating that the decorated Gal4 variant can be delivery into cells where it still retains its transcription factor capacities. Thus, we have produced in E. coli and purified a short active form of Gal4 that retains its functions at the surface of PLA-nanoparticles in cellular assay. These decorated Gal4-nanoparticles will be useful to decipher their tissue distribution and their potential after ingestion or injection in UAS-GFP recombinant animal models.
Collapse
Affiliation(s)
- Sophie Legaz
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS UMR 5305, 7 passage du Vercors, 69367 Lyon, France
| | - Jean-Yves Exposito
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS UMR 5305, 7 passage du Vercors, 69367 Lyon, France
| | - Agnès Borel
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS UMR 5305, 7 passage du Vercors, 69367 Lyon, France
| | - Marie-Pierre Candusso
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Bases Moléculaires et Structurales des Systèmes Infectieux, CNRS UMR 5086, 7 passage du Vercors, 69367 Lyon, France
| | - Simon Megy
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS UMR 5305, 7 passage du Vercors, 69367 Lyon, France
| | - Roland Montserret
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Bases Moléculaires et Structurales des Systèmes Infectieux, CNRS UMR 5086, 7 passage du Vercors, 69367 Lyon, France
| | - Vincent Lahaye
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS UMR 5305, 7 passage du Vercors, 69367 Lyon, France
| | - Christophe Terzian
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Infection et Evolution des Génomes Viraux, INRA-UCBL UMR754, 69367 Lyon, France
| | - Bernard Verrier
- Institut de Biologie et Chimie des Protéines, FR3302, SFR BioSciences (UMS3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France; Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS UMR 5305, 7 passage du Vercors, 69367 Lyon, France.
| |
Collapse
|
65
|
Kim YD, Park TE, Singh B, Maharjan S, Choi YJ, Choung PH, Arote RB, Cho CS. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Nanomedicine (Lond) 2015; 10:1165-88. [DOI: 10.2217/nnm.14.214] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than 15% even after the treatment. Unfortunately, chemotherapeutic treatments for lung cancer are accompanied by severe side effects, lack of selectivity and multidrug resistance. In order to overcome the limitations of conventional chemotherapy, nanoparticle-mediated RNA interference drugs represent a potential new approach due to selective silencing effect of oncogenes and multidrug resistance related genes. In this review, we provide recent advancements on nanoparticle-mediated siRNA delivery strategies including lipid system, polymeric system and rigid nanoparticles for lung cancer therapies. Importantly, codelivery of siRNA with conventional anticancer drugs and recent theranostic agents that offer great potential for lung cancer therapy is covered.
Collapse
Affiliation(s)
- Young-Dong Kim
- Department of Molecular Genetics, Dental Research Institute, School of Dentistry, Seoul National University, Seoul 110-749, Republic of Korea
| | - Tae-Eun Park
- Department of Agricultural Biotechnology & Research Institute for Agriculture & Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea
| | - Bijay Singh
- Department of Agricultural Biotechnology & Research Institute for Agriculture & Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea
| | - Sushila Maharjan
- Department of Agricultural Biotechnology & Research Institute for Agriculture & Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea
| | - Yun-Jaie Choi
- Department of Agricultural Biotechnology & Research Institute for Agriculture & Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea
| | - Pill-Hoon Choung
- Department of Oral & Maxillofacial Surgery & Dental Research Institute, School of Dentistry, Seoul National University, Seoul 110-749, Republic of Korea
| | - Rohidas B. Arote
- Department of Molecular Genetics, Dental Research Institute, School of Dentistry, Seoul National University, Seoul 110-749, Republic of Korea
| | - Chong-Su Cho
- Department of Agricultural Biotechnology & Research Institute for Agriculture & Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea
| |
Collapse
|
66
|
Braoudaki M, Lambrou GI. MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown. J Hematol Oncol 2015; 8:6. [PMID: 25652781 PMCID: PMC4333163 DOI: 10.1186/s13045-014-0101-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2014] [Accepted: 12/27/2014] [Indexed: 12/16/2022] Open
Abstract
MicroRNAs (miRNAs) are endogenous short non-coding RNAs that repress post-transcriptional regulation of gene expression, while embryonal central nervous system tumors are the foremost cause of mortality in children suffering from a neoplasm. MiRNAs and their regulatory mechanisms are new to understand, while pediatric CNS tumors are difficult to comprehend. Therefore, identification of the link between them composes a major scientific challenge. The present study, reviewed the current knowledge on the role of miRNA in pediatric CNS embryonal tumors, attempting to collect the existing information in one piece of work that could ideally be used as a guide for future reference and research.
Collapse
Affiliation(s)
- Maria Braoudaki
- First Department of Pediatrics, University of Athens, Choremeio Research Laboratory, Athens, Greece. .,University Research Institute for the Study and Treatment of Childhood Genetic and Malignant Diseases, University of Athens, Aghia Sophia Children's Hospital, Athens, Greece.
| | - George I Lambrou
- First Department of Pediatrics, University of Athens, Choremeio Research Laboratory, Athens, Greece.
| |
Collapse
|
67
|
Electrochemical synthesis, characterisation and phytogenic properties of silver nanoparticles. APPLIED NANOSCIENCE 2015. [DOI: 10.1007/s13204-014-0396-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
68
|
Astafyeva K, Thomas JL, Coulouvrat F, Guédra M, Diou O, Mousnier L, Tsapis N, Urbach W, Taulier N. Properties of theranostic nanoparticles determined in suspension by ultrasonic spectroscopy. Phys Chem Chem Phys 2015; 17:25483-93. [DOI: 10.1039/c5cp04424c] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We use ultrasound spectroscopy to determine viscosity, radii and shell thickness distribution of nanoparticles in suspension.
Collapse
Affiliation(s)
- Ksenia Astafyeva
- Sorbonne Universités
- UPMC Univ Paris 06
- CNRS-UMR 7588
- Institut des NanoSciences de Paris
- Paris
| | - Jean-Louis Thomas
- Sorbonne Universités
- UPMC Univ Paris 06
- CNRS-UMR 7588
- Institut des NanoSciences de Paris
- Paris
| | - François Coulouvrat
- Sorbonne Universités
- UPMC Univ Paris 06
- CNRS-UMR 7190
- Institut Jean Le Rond d'Alembert
- Paris
| | - Matthieu Guédra
- Sorbonne Universités
- UPMC Univ Paris 06
- CNRS-UMR 7190
- Institut Jean Le Rond d'Alembert
- Paris
| | - Odile Diou
- Institut Galien Paris-Sud
- UMR CNRS 8612
- Labex LERMIT
- Châtenay-Malabry
- France
| | - Ludivine Mousnier
- Institut Galien Paris-Sud
- UMR CNRS 8612
- Labex LERMIT
- Châtenay-Malabry
- France
| | - Nicolas Tsapis
- Institut Galien Paris-Sud
- UMR CNRS 8612
- Labex LERMIT
- Châtenay-Malabry
- France
| | - Wladimir Urbach
- Sorbonne Universités
- UPMC Univ Paris 06
- CNRS
- INSERM
- Laboratoire d'Imagerie Biomédicale
| | - Nicolas Taulier
- Sorbonne Universités
- UPMC Univ Paris 06
- CNRS
- INSERM
- Laboratoire d'Imagerie Biomédicale
| |
Collapse
|
69
|
Seeta Rama Raju G, Benton L, Pavitra E, Yu JS. Multifunctional nanoparticles: recent progress in cancer therapeutics. Chem Commun (Camb) 2015; 51:13248-59. [DOI: 10.1039/c5cc04643b] [Citation(s) in RCA: 115] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
In recent times, several biocompatible nanomaterials with different morphologies and compositions, such as metals, metal oxides, and polymers, have been employed as multi-functional biomaterials to target cancer cells.
Collapse
Affiliation(s)
- G. Seeta Rama Raju
- Department of Electronics and Radio Engineering
- Optoelectronics and Nanodevices Laboratory
- Kyung Hee University
- Yongin-si
- Republic of Korea
| | - Leah Benton
- Department of Biology
- Emory University
- Atlanta
- USA
| | - E. Pavitra
- Department of Electronics and Radio Engineering
- Optoelectronics and Nanodevices Laboratory
- Kyung Hee University
- Yongin-si
- Republic of Korea
| | - Jae Su Yu
- Department of Electronics and Radio Engineering
- Optoelectronics and Nanodevices Laboratory
- Kyung Hee University
- Yongin-si
- Republic of Korea
| |
Collapse
|
70
|
Dhand C, Dwivedi N, Loh XJ, Jie Ying AN, Verma NK, Beuerman RW, Lakshminarayanan R, Ramakrishna S. Methods and strategies for the synthesis of diverse nanoparticles and their applications: a comprehensive overview. RSC Adv 2015. [DOI: 10.1039/c5ra19388e] [Citation(s) in RCA: 398] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Various methods to synthesize diverse nanoparticles with their different applications.
Collapse
Affiliation(s)
- Chetna Dhand
- Anti-Infectives Research Group
- Singapore Eye Research Institute
- Singapore 169856
| | - Neeraj Dwivedi
- Department of Electrical and Computer Engineering
- National University of Singapore
- Singapore 117582
| | - Xian Jun Loh
- Institute of Materials Research and Engineering
- A*STAR (Agency for Science, Technology and Research)
- Singapore 117602
| | - Alice Ng Jie Ying
- Anti-Infectives Research Group
- Singapore Eye Research Institute
- Singapore 169856
| | - Navin Kumar Verma
- Anti-Infectives Research Group
- Singapore Eye Research Institute
- Singapore 169856
- Lee Kong Chian School of Medicine
- Nanyang Technological University
| | - Roger W. Beuerman
- Anti-Infectives Research Group
- Singapore Eye Research Institute
- Singapore 169856
- Duke-NUS SRP Neuroscience and Behavioral Disorders
- Singapore 169857
| | - Rajamani Lakshminarayanan
- Anti-Infectives Research Group
- Singapore Eye Research Institute
- Singapore 169856
- Duke-NUS SRP Neuroscience and Behavioral Disorders
- Singapore 169857
| | - Seeram Ramakrishna
- Center for Nanofibers and Nanotechnology
- Department of Mechanical Engineering
- National University of Singapore
- Singapore 117576
| |
Collapse
|
71
|
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 2014; 194:238-56. [PMID: 25204288 DOI: 10.1016/j.jconrel.2014.09.001] [Citation(s) in RCA: 274] [Impact Index Per Article: 24.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 08/29/2014] [Accepted: 09/01/2014] [Indexed: 12/21/2022]
Abstract
Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibit drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms, etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), multidrug resistant protein 1 (MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.
Collapse
|
72
|
André ND, Silva VAO, Watanabe MAE, De Lucca FL. Intratumoral injection of PKR shRNA expressing plasmid inhibits B16-F10 melanoma growth. Oncol Rep 2014; 32:2267-73. [PMID: 25175769 DOI: 10.3892/or.2014.3410] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Accepted: 08/04/2014] [Indexed: 11/06/2022] Open
Abstract
The RNA-dependent protein kinase (PKR) is a serine/threonine kinase that is involved in the regulation of important cell processes such as apoptosis, signal transduction, cell proliferation and differentiation. However, the role played by PKR in cancer remains controversial. RNA interference (RNAi) has currently become an important technique in understanding gene function. Previously, we showed that PKR shRNA downregulates PKR expression in B16-F10 melanoma cells and reduces the metastatic potential of these tumor cells. In the present study, we examined the effect of the intratumoral injection of PKR shRNA‑expressing plasmid on the growth of B16-F10 melanoma in mice. The results showed that this treatment significantly reduced tumor growth. Thus, these findings suggested that PKR acts as a tumor suppressor, a finding that is consistent with our previous study on the experimental model of metastasis. Moreover, the results suggested that this effect may be mediated by the transcription factor NF-κB. The present study confirmed the hypothesis that the direct administration of RNAi-based therapeutics in the target tumor is a promising approach for overcoming the obstacles of systemic delivery. The results also suggested that the intratumoral injection of PKR shRNA‑expressing vector is a novel therapeutic approach for human solid tumors such as cutaneous melanoma and breast cancer, since PKR is overexpressed in these tumors.
Collapse
Affiliation(s)
| | - Viviane Aline Oliveira Silva
- Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, 14049-900 Ribeirão Preto, SP, Brazil
| | - Maria Angelica Ehara Watanabe
- Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, 86057-970 Londrina, PR, Brazil
| | - Fernando Luiz De Lucca
- Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, 14049-900 Ribeirão Preto, SP, Brazil
| |
Collapse
|
73
|
Vitiello M, Tuccoli A, Poliseno L. Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol (Dordr) 2014; 38:17-28. [PMID: 25113790 DOI: 10.1007/s13402-014-0180-x] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/07/2014] [Indexed: 02/06/2023] Open
Abstract
Long non-coding RNAs (lncRNAs, pseudogenes and circRNAs) have recently come into light as powerful players in cancer pathogenesis and it is becoming increasingly clear that they have the potential of greatly contributing to the spread and success of personalized cancer medicine. In this concise review, we briefly introduce these three classes of long non-coding RNAs. We then discuss their applications as diagnostic and prognostic biomarkers. Finally, we describe their appeal as targets and as drugs, while pointing out the limitations that still lie ahead of their definitive entry into clinical practice.
Collapse
Affiliation(s)
- Marianna Vitiello
- Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori c/o IFC-CNR, via Moruzzi 1, 56124, Pisa, Italy
| | | | | |
Collapse
|